Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company

Core Insights - Organovo Holdings, Inc. is set to be acquired by Eli Lilly and Company, specifically for its FXR program, which includes the lead asset FXR314 [1][2] - This acquisition represents a significant milestone in advancing treatments for inflammatory bowel disease (IBD) using Organovo's proprietary 3D human tissue models [2] Company Overview - Organovo is a clinical stage biotechnology company focused on developing drugs that are effective in three-dimensional (3D) human tissues [3] - The company utilizes proprietary technology to create 3D human tissues that replicate key aspects of native human tissue composition, architecture, function, and disease [3] Transaction Details - Under the terms of the acquisition, Organovo will receive an upfront payment along with milestone payments as FXR314 meets key regulatory and commercial milestones [2] - Eli Lilly will acquire all commercial and intellectual property rights to Organovo's FXR program for worldwide development [2]